Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Novartis is making the largest single-modality bet in pharma on molecular glues. Four deals. Two partners (Orionis, Monte Rosa). More than $7.1B in potential milestones. The commitment is striking because molecular glues are still an emerging modality. No molecular glue has been approved as a standalone therapy (though BMS's CELMoD mezigdomide, a related cereblon modulator, is in late-stage development for myeloma). The appeal: molecular glues are small molecules that redirect the cell's own protein degradation machinery (the ubiquitin-proteasome system) to destroy disease-causing proteins. Unlike traditional small molecule inhibitors (which block a protein's function), molecular glues physically eliminate the target protein from the cell. This makes historically "undruggable" proteins accessible for the first time. Novartis's head of discovery sciences John Tallarico said Orionis's technology "offers an opportunity to rapidly uncover and design molecular glue mechanisms, enabling us to expand the horizon of targetable biology for future therapies." BioSpace noted this is Novartis's second deal with Orionis (the first was in March 2020) and that the pharma is "returning to its preferred molecular glue partners." Separately, the survodutide fat composition data are worth watching. If the drug preferentially reduces fat while preserving lean mass, it occupies a differentiated position alongside GSK/SiranBio's ALK7 inhibitor (same thesis) rather than competing head-to-head with Wegovy and Zepbound on total weight loss. 👉 Read Full Analysis

🔮 What To Watch

🏢 Corporate & Business Developments

Novartis Deepens Molecular Glue Commitment with $1.4B Orionis Deal NVS

Novartis signed a multi-year collaboration with Orionis Biosciences on June 10 to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. Orionis receives $40M upfront and is eligible for up to $1.4B in research, development, and commercial milestone payments, plus tiered royalties on net sales. The deal uses Orionis's Allo-Glue platform combined with its AI-driven discovery engine to accelerate target and ligase profiling and molecular glue optimization. CEO Niko Kley said: "Having such a partner continue to engage deeply with us is a strong validation of the value of our molecular glue platform."

This is Novartis's fourth molecular glue deal:

Total committed milestone value across the four deals exceeds $7.1B. No other pharma company has invested this heavily in molecular glue technology.

🌍 Policy

EFPIA Urges EU to Widen Biotech Act Patent Incentive

The European Federation of Pharmaceutical Industries and Associations (EFPIA) urged EU lawmakers on June 15 to broaden a proposed patent-style incentive in the Biotech Act, warning that the current plan is too narrow to materially shift investment decisions, according to The Pharma Letter. The push comes as European pharma companies navigate the EU Critical Medicines Act (agreed May 22), Germany's healthcare reform (which prompted Lilly and Boehringer to pull $1B+ each), and the competitive pressure of U.S. onshoring incentives under Section 232. EFPIA's argument: if the EU wants to retain biopharma R&D investment, its patent incentives must be competitive with the U.S. framework.

🔬 Gene Therapy

SonoThera Raises $125M for Ultrasound-Mediated Gene Therapy Delivery

SonoThera raised $125M in a Series B to advance safer gene therapies delivered through ultrasound-mediated technology rather than viral vectors, according to BioSpace. The approach could help sidestep the safety concerns that have emerged around AAV-based gene therapy this year (REGENXBIO Duchenne adverse events, the AAV-linked brain tumor case). Non-viral delivery methods are gaining investor interest as the gene therapy field grapples with the risk-benefit trade-off of viral vectors. Lilly's Engage Biologics acquisition (non-viral DNA delivery) and Profluent collaboration (AI-designed recombinases) pursue the same broad thesis through different technology approaches.

💊 GLP-1 & Obesity

Survodutide: Underwhelming Weight Loss but Impressive Fat Composition

BioSpace reported that Boehringer Ingelheim and Zealand Pharma's survodutide achieved 16.6% overall weight loss in its Phase 3 obesity trial. BMO Capital Markets called the weight loss "underwhelming" compared with Wegovy (~15-17%), Zepbound (~22%), and retatrutide (~28%). However, BMO described the fat loss composition as "impressive," suggesting survodutide may preferentially reduce fat while preserving lean mass. This is the same thesis behind GSK/SiranBio's ALK7 inhibitor ($1B deal, May 6) and Arrowhead's ARO-ALK7. If confirmed, survodutide could carve out a niche as a body composition optimizer rather than a maximum weight loss drug, complementing GLP-1 therapy rather than competing with it directly.

📅 The Week Ahead

Molecular glues work through "induced proximity": they bring a disease-causing protein into physical contact with a ligase enzyme, which tags the protein for destruction by the cell's own proteasome. Unlike protein degraders (PROTACs), which are larger bifunctional molecules, molecular glues are small molecules with better drug-like properties (oral bioavailability, tissue penetration, manufacturing simplicity).

Novartis's investment logic: if molecular glues can systematically access "undruggable" targets (proteins without traditional binding pockets), they open a therapeutic space that no existing modality can reach. The AI-driven discovery engines (Orionis Allo-Glue, Monte Rosa) are designed to identify productive target-ligase pairs at scale, turning what was previously a serendipitous discovery process into a systematic platform.

The risk: no molecular glue has been approved as a standalone therapy. BMS's mezigdomide (CELMoD, cereblon modulator) is the closest, but it is technically a cereblon E3 ligase modulator rather than a true "molecular glue" in the emerging definition. Novartis is betting $7B+ that the platform approach will yield multiple clinical candidates across oncology, immunology, and potentially neuroscience. The payoff is years away but the strategic commitment is unmistakable.

💊 The Obesity Drug Landscape: Weight vs. Composition

The GLP-1 market is segmenting along a new axis: total weight loss versus body composition quality.

If body composition matters clinically (and evidence increasingly suggests it does, especially in older patients and those at sarcopenia risk), drugs like survodutide and ALK7 inhibitors occupy a differentiated niche that total-weight-loss leaders like retatrutide and Zepbound cannot easily replicate.

📊 Non-Viral Gene Therapy: Three Approaches

All three approaches aim to solve the same problem: deliver genetic material to cells without using viral vectors (AAV, lentivirus) that carry immunogenicity and insertional oncogenesis risks. The gene therapy field's 2026 safety signals (REGENXBIO Duchenne, AAV brain tumor) have increased urgency around non-viral alternatives.

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →